In breast cancer, Wan et al., found that METTL3/IGF2BP3 upregulates the expression of PD-L1 epigenetically, leading to a PD-L1-dependent T cell exhaustion and infiltration [142], suggesting METTL3/IGF2BP3-mediated m6A modification might be a novel immunotherapeutic target. The gene discussed is CD274; the disease is breast cancer.